Abivax (ABVX) Announces $150M ATM Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall Street ends down sharply, worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Vertiv shares fall on analyst downgrades and options bets
- Stocks slip as dollar heads for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
November 19, 2024 4:30 PM ESTAbivax Establishes an At-the-Market (ATM) Program on Nasdaq
PARIS, France, November 19, 2024 10:30PM CET Abivax SA (Euronext Paris: FR0012333284 ABVX / Nasdaq - ABVX) (Abivax or the Company), a clinical-stage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, today announced the implementation of an At-The-Market program (ATM Program) allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in... More



